Revvity Inc vs Tripadvisor Inc Common Stock — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Tripadvisor Inc Common Stock trades at $8.79 (market cap $1.07B). The key difference: Revvity Inc is far larger — about 13.3× Tripadvisor Inc Common Stock's market cap, and Revvity Inc pays a 0.22% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| RVTY | TRIP | |
|---|---|---|
Market Cap | $14.18B | $1.07B |
Sector | Technology | Consumer Cyclical |
52-Week High | $130.94 | $19.14 |
52-Week Low | $82.26 | $8.82 |
Enterprise Value | $16.50B | $1.12B |
Dividend Yield | 0.22% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Tripadvisor (TRIP) trades at $9.085, down 2.57% for the day, reflecting ongoing pressure from recent earnings misses and competitive challenges. The stock shows bearish technical signals with mixed oscillators, while fundamentals reveal strong gross margins (92.11%) but thin net income (0.27%). Recent news highlights insider selling and TheFork subsidiary sale, creating uncertainty about growth prospects amid AI-driven travel competition.
The outlook remains cautious with analyst consensus leaning Hold (62.5%) despite a $11.80 price target suggesting 30% upside. Key risks include persistent earnings volatility, market share erosion to AI platforms, and declining cash flow trends. Investment opportunity hinges on Viator's performance and successful execution of strategic initiatives post-TheFork divestiture.
Trailing returns across standard periods
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →